$PCRX News

Last published 1w ago

1w agoVTRS PCRXViatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.PR NewswirePITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of
1mo agoBOLD OPCH PCRX RXOAre OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
1mo agoVTRS PCRXViatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPR NewswireAdds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S.
1mo agoPCRXPacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at HomeGlobeNewswireCaregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira
2mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
3mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
3mo agoPCRXPacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic DiseasesGlobeNewswire— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed
3mo agoPCRXPacira BioSciences Reports Second Quarter 2026 Financial ResultsGlobeNewswire-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million,
3mo agoPCRXPacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s WorkforceGlobeNewswire- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - BRISBANE, Calif., July 28, 2026 (GLOBE
3mo agoPCRXPacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing ProcessGlobeNewswire— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process —— Topline data from Part A of Phase 2 ASCEND study remains on track for end of year —
3mo agoPCRXPacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026GlobeNewswireBRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
4mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
4mo agoPCRXPacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®GlobeNewswire-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in
4mo agoPCRXPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer BiometGlobeNewswire-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity
5mo agoPCRXPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingPR NewswirePacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain...
5mo agoPCRXPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingPR NewswirePacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain...
5mo agoPCRXPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesPR NewswirePacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain...
5mo agoPCRXLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director NomineesGlobeNewswireBRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform
5mo agoPCRXPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified NomineesGlobeNewswireClarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
5mo agoCNXU ESTA INMD PCRX+1After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadGlobeNewswireConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue
5mo agoPCRXPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder ArthroplastyGlobeNewswireFindings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira
5mo agoPCRXPacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property StrategyGlobeNewswireUrges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company"
5mo agoCNXU ELUT PCRX SNN+1A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingGlobeNewswireFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary —
5mo agoPCRXA LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLCPR NewswireDOMA Perpetual Capital Management ("DOMA Perpetual"), which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns...
5mo agoPCRXDOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira BiosciencesPR NewswireDOMA Perpetual Capital Management ("DOMA Perpetual") which, together with its affiliates (collectively "DOMA" or "we"), beneficially owns...
5mo agoPCRXPacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All StockholdersGlobeNewswireUrges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company"
6mo agoPCRXDOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board CandidatesPR NewswireDOMA Perpetual Capital Management ("DOMA Perpetual"), which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns...
6mo agoPCRXPacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare ConferencesGlobeNewswireBRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
6mo agoBMY PCRXPacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board NomineesGlobeNewswireHighlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
6mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
6mo agoPCRXPacira BioSciences Mails Letter to StockholdersGlobeNewswireDetails Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board's Unanimous Recommendation that Stockholders Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE
6mo agoPCRXPacira BioSciences Reports First Quarter 2026 Financial ResultsGlobeNewswire-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3
6mo agoPCRXPacira BioSciences Files Definitive Proxy Materials and Mails Letter to ShareholdersGlobeNewswireUrges Stockholders to Vote "FOR" Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA's Underqualified Nominees BRISBANE, Calif., April 28, 2026 (GLOBE
6mo agoPCRXReal-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip ArthroplastyGlobeNewswireBRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
6mo agoPCRXPacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026GlobeNewswireBRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
7mo agoPCRXPacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresGlobeNewswire-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total
7mo agoPCRXPacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
7mo agoPCRXPacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual MeetingGlobeNewswire-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira
8mo agoPCRXDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.PR NewswireDOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with its affiliates...
8mo agoPCRXDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.PR NewswireDOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with its affiliates...
8mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
8mo agoPCRXPacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare ConferenceGlobeNewswireBRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
8mo agoPCRXPacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)GlobeNewswire-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American
8mo agoPCRXPacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE
9mo agoPCRXPacira to Report 2025 Financial Results on Thursday February 26, 2026GlobeNewswireBRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients,
9mo agoPCRXPacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid ChoicesGlobeNewswireBRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings
9mo agoPCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today
9mo agoPCRXPacira BioSciences Appoints Samit Hirawat, M.D., to Board of DirectorsGlobeNewswire-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its
10mo agoPCRXPacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific MarketsGlobeNewswire-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira
10mo agoPCRXPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 RevenuesGlobeNewswire-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.